MEIS2
Basic information
Region (hg38): 15:36889204-37101299
Links
Phenotypes
GenCC
Source:
- cardiac malformation, cleft lip/palate, microcephaly, and digital anomalies (Moderate), mode of inheritance: AD
- cardiac malformation, cleft lip/palate, microcephaly, and digital anomalies (Definitive), mode of inheritance: AD
- syndromic intellectual disability (Definitive), mode of inheritance: AD
- neurodevelopmental disorder (Strong), mode of inheritance: AD
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Cleft palate, cardiac defects, and impaired intellectual development | AD | Cardiovascular | The condition can involve congenital cardiac anomalies, and awareness may allow early identifcation and management | Cardiovascular; Craniofacial; Musculoskeletal; Neurologic | 24678003; 25712757; 26561393; 27225850 |
ClinVar
This is a list of variants' phenotypes submitted to
- Cardiac_malformation,_cleft_lip/palate,_microcephaly,_and_digital_anomalies (100 variants)
- not_provided (49 variants)
- Inborn_genetic_diseases (46 variants)
- MEIS2-related_disorder (14 variants)
- Cleft_palate (2 variants)
- not_specified (2 variants)
- Cleft_lip/palate (1 variants)
- Syndromic_intellectual_disability (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the MEIS2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000170675.5. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 29 | 37 | ||||
| missense | 13 | 72 | 98 | |||
| nonsense | 12 | |||||
| start loss | 0 | |||||
| frameshift | 12 | |||||
| splice donor/acceptor (+/-2bp) | 7 | |||||
| Total | 19 | 22 | 80 | 35 | 10 |
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| MEIS2 | protein_coding | protein_coding | ENST00000561208 | 12 | 212099 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.999 | 0.000617 | 125642 | 0 | 5 | 125647 | 0.0000199 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 2.46 | 171 | 288 | 0.593 | 0.0000145 | 3167 |
| Missense in Polyphen | 19 | 76.782 | 0.24745 | 928 | ||
| Synonymous | -0.239 | 113 | 110 | 1.03 | 0.00000657 | 901 |
| Loss of Function | 4.52 | 1 | 25.7 | 0.0389 | 0.00000126 | 284 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.0000289 | 0.0000289 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.00 | 0.00 |
| Finnish | 0.00 | 0.00 |
| European (Non-Finnish) | 0.0000187 | 0.0000176 |
| Middle Eastern | 0.00 | 0.00 |
| South Asian | 0.0000654 | 0.0000653 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in transcriptional regulation. Binds to HOX or PBX proteins to form dimers, or to a DNA-bound dimer of PBX and HOX proteins and thought to have a role in stabilization of the homeoprotein-DNA complex. Isoform 3 is required for the activity of a PDX1:PBX1b:MEIS2b complex in pancreatic acinar cells involved in the transcriptional activation of the ELA1 enhancer; the complex binds to the enhancer B element and cooperates with the transcription factor 1 complex (PTF1) bound to the enhancer A element; MEIS2 is not involved in complex DNA-binding. Probably in complex with PBX1, is involved in transcriptional regulation by KLF4. Isoform 3 and isoform 4 can bind to a EPHA8 promoter sequence containing the DNA motif 5'-CGGTCA-3'; in cooperation with a PBX protein (such as PBX2) is proposed to be involved in the transcriptional activation of EPHA8 in the developing midbrain. May be involved in regulation of myeloid differentiation. Can bind to the DNA sequence 5'-TGACAG-3'in the activator ACT sequence of the D(1A) dopamine receptor (DRD1) promoter and activate DRD1 transcription; isoform 5 cannot activate DRD1 transcription. {ECO:0000269|PubMed:10764806, ECO:0000269|PubMed:11279116, ECO:0000269|PubMed:21746878}.;
- Disease
- DISEASE: Cleft palate, cardiac defects, and mental retardation (CPCMR) [MIM:600987]: An autosomal dominant disease characterized by multiple congenital malformations, mild-to-severe intellectual disability with poor speech, and delayed psychomotor development. Congenital malformations include heart defects, cleft lip/palate, distally-placed thumbs and toes, and cutaneous syndactyly between the second and third toes. {ECO:0000269|PubMed:24678003, ECO:0000269|PubMed:25712757, ECO:0000269|PubMed:27225850}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.163
Intolerance Scores
- loftool
- 0.0910
- rvis_EVS
- -0.4
- rvis_percentile_EVS
- 26.53
Haploinsufficiency Scores
- pHI
- 0.621
- hipred
- Y
- hipred_score
- 0.768
- ghis
- 0.548
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.977
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Meis2
- Phenotype
- vision/eye phenotype; digestive/alimentary phenotype; hearing/vestibular/ear phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); skeleton phenotype; liver/biliary system phenotype; embryo phenotype; growth/size/body region phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); craniofacial phenotype; cellular phenotype;
Zebrafish Information Network
- Gene name
- meis2a
- Affected structure
- cranial cartilage
- Phenotype tag
- abnormal
- Phenotype quality
- mislocalised
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;eye development;transcription by RNA polymerase II;visual learning;response to mechanical stimulus;pancreas development;negative regulation of myeloid cell differentiation;positive regulation of mitotic cell cycle;positive regulation of transcription by RNA polymerase II;response to growth factor;positive regulation of cardiac muscle myoblast proliferation
- Cellular component
- nucleus;perinuclear region of cytoplasm
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;DNA binding;DNA-binding transcription factor activity;transcription coregulator activity;transcription corepressor activity;protein binding;transcription factor binding